| DISEASE | TITLE OF PUBLICATION | LINK TO PUBMED |
| Adenocarcinoma | Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. |  PubMed |
| Adenocarcinoma | Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro. | PubMed |
| Adenocarcinoma | Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. | PubMed |
| Adenocarcinoma | Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). | PubMed |
| Adenocarcinoma | The ability of coumarin-, flavanon- and flavonol-analogues of flavone acetic acid to stimulate human monocytes. | PubMed |
| Adenoma | [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland] | PubMed |
| Alkaptonuria | In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I. | PubMed |
| Anemia | Folate status and folate related anemia: a comparative cross-sectional study of long-term care and post-acute care psychogeriatric patients. | PubMed |
| Aneurysm | Clinical relationship between femoral artery aneurysms and arteriomegaly. | PubMed |
| Aneurysm | Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. | PubMed |
| Aneurysm | Recurrent femoral anastomotic aneurysms. A 30-year experience. | PubMed |
| Aneurysm | [Anastomotic pseudoaneurysm, true para-anastomotic aneurysm and recurrent aneurysm following surgery for abdominal aortic aneurysm. Is a unifying theory possible?] | PubMed |
| Arthritis, Experimental | Inverse relationship of hippocampal serotonin to avoidance behavior, serotonergic activation by emotional stress differentiated by estrous cycle and surgical stress. | PubMed |
| Atrial Fibrillation | Electrophysiologic properties of atrial muscle in paroxysmal atrial fibrillation. | PubMed |
| Bone Resorption | Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. | PubMed |
| Brain Death | Does brain death induce a pro-inflammatory response at the organ level in a porcine model? | PubMed |
| Brain Injuries | Attenuation of brain free fatty acid liberation during global ischemia: a model for screening potential therapies for efficacy? | PubMed |
| Brain Ischemia | The influence of MK-801 on the hippocampal free arachidonic acid level and Na+,K+-ATPase activity in global cerebral ischemia-exposed rats. | PubMed |
| Breast Neoplasms | Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3. | PubMed |
| Breast Neoplasms | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). | PubMed |
| Carcinoma | Combined treatments of heat, radiation, or cytokines with flavone acetic acid on the growth of cultured endothelial cells. | PubMed |
| Carcinoma | Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft. | PubMed |
| Carcinoma | Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). | PubMed |
| Carcinoma | Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. | PubMed |
| Carcinoma | [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland] | PubMed |
| Carcinoma, Hepatocellular | Effects of carbon tetrachloride and azathioprine on diethylnitrosamine and N-2-fluorenylacetamide-induced hyperplastic liver nodule and hepatocellular carcinoma. | PubMed |
| Carcinoma, Hepatocellular | Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. | PubMed |
| Carcinoma, Hepatocellular | Enzyme deviation patterns in primary rat hepatomas induced by sequential administration of two chemically different carcinogens. | PubMed |
| Carcinoma, Hepatocellular | Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. | PubMed |
| Carcinoma, Lewis Lung | Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). | PubMed |
| Carcinoma, Papillary | [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland] | PubMed |
| Carcinoma, Squamous Cell | 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. | PubMed |
| Carcinoma, Squamous Cell | Combined treatments of heat, radiation, or cytokines with flavone acetic acid on the growth of cultured endothelial cells. | PubMed |
| Cell Transformation, Neoplastic | Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis. | PubMed |
| Colonic Neoplasms | Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells. | PubMed |
| Colonic Neoplasms | Flavone acetic acid suppresses human peripheral blood lymphocyte and human colonic lamina propria lymphocyte DNA synthesis. | PubMed |
| Colonic Neoplasms | The activity of flavone acetic acid (NSC 347512) on human colon cancer cells in vitro. | PubMed |
| Colorectal Neoplasms | Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. | PubMed |
| Coronary Artery Disease | A comparison of postmortem coronary atherosclerosis findings in general aviation pilot fatalities. | PubMed |
| Cysts | Diaphragmatic mesothelial cyst in a child with Fanconi aplastic anemia. | PubMed |
| Cysts | Echinococcus granulosus: a comparison of free amino acid concentration in hydatid fluid from primary and secondary cysts and host plasma. | PubMed |
| Cysts | Effect of mebendazole on free amino acid composition of cyst wall and cyst fluid of Echinococcus granulosus harbored in mice. | PubMed |
| Deafness | Hearing deficit in a birth cohort of U.S. male commuter air carrier and air taxi pilots. | PubMed |
| Dehydration | Effects of fixation and dehydration procedures on marine nematodes. | PubMed |
| Diabetes Mellitus | Femoral anastomotic aneurysms: a continuing challenge. | PubMed |
| Dystonia | Dystonia, botulinum neurotoxin, and the aviator. | PubMed |
| Fanconi Anemia | Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. | PubMed, PubMed |
| Fanconi Anemia | Functional activity of the fanconi anemia protein FAA requires FAC binding and nuclear localization. | PubMed |
| Fanconi Anemia | Identification of Alu-mediated deletions in the Fanconi anemia gene FAA. | PubMed |
| Fanconi Anemia | Normal expression of the Fanconi anemia proteins FAA and FAC and sensitivity to mitomycin C in two patients with Seckel syndrome. | PubMed |
| Fanconi Anemia | Sequence variation in the Fanconi anemia gene FAA. | PubMed |
| Fanconi Anemia | The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. | PubMed |
| Fanconi Anemia | The fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation. | PubMed |
| Fanconi Anemia | The Fanconi anemia proteins FAA and FAC function in different cellular compartments to protect against cross-linking agent cytotoxicity. | PubMed |
| Fibrosarcoma | Effect of environmental conditions (pH, oxygenation and temperature) on the cytotoxicity of flavone acetic acid and its dimethylaminoethyl ester. | PubMed |
| Fibrosarcoma | Flavone acetic acid as a modifier of endothelial cell function. | PubMed |
| fumarylacetoacetase deficiency | A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report. | PubMed |
| fumarylacetoacetase deficiency | Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency. | PubMed |
| fumarylacetoacetase deficiency | Cell fusion is the principal source of bone-marrow-derived hepatocytes. | PubMed |
| fumarylacetoacetase deficiency | Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue. | PubMed |
| fumarylacetoacetase deficiency | Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer. | PubMed |
| fumarylacetoacetase deficiency | Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). | PubMed |
| fumarylacetoacetase deficiency | Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. | PubMed |
| fumarylacetoacetase deficiency | Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. | PubMed |
| fumarylacetoacetase deficiency | Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. | PubMed |
| fumarylacetoacetase deficiency | Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. | PubMed |
| fumarylacetoacetase deficiency | Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. | PubMed |
| fumarylacetoacetase deficiency | Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia. | PubMed |
| fumarylacetoacetase deficiency | The nephropathy of type I tyrosinemia after liver transplantation. | PubMed |
| fumarylacetoacetase deficiency | The pathophysiology and treatment of hereditary tyrosinemia type 1. | PubMed |
| fumarylacetoacetase deficiency | The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase. | PubMed |
| fumarylacetoacetase deficiency | Tyrosinaemia--treatment and outcome. | PubMed |
| Glioma | Deregulation of ion channel and transporter encoding genes in pediatric gliomas. | PubMed |
| Goiter, Nodular | [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland] | PubMed |
| Graves Disease | Evidence for anti-tubulin autoantibodies in the form of immune complexes in human sera. | PubMed |
| Hashimoto Disease | [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland] | PubMed |
| Heart Diseases | Recurrent femoral anastomotic aneurysms. A 30-year experience. | PubMed |
| Heart Failure | [False anastomotic aneurysms after aorto-femoral prosthesis. Detection, prevention and treatment] | PubMed |
| Hepatitis | Autoimmune hepatitis-like disease in C57BL/6 mice infected with mouse hepatitis virus A59. | PubMed |
| Hepatitis | Detection of mouse hepatitis virus infection by assay of anti-liver autoantibodies. | PubMed |
| Hepatitis | Fine specificity of autoantibodies induced by mouse hepatitis virus A59. | PubMed |
| Hepatitis | Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis. | PubMed |
| Hepatitis | Sequence similarity and structural homologies are involved in the autoimmune response elicited by mouse hepatitis virus A59. | PubMed |
| Hepatitis | The peptide specificities of the autoantibodies elicited by mouse hepatitis virus A59. | PubMed |
| Hepatitis | Uric acid and HMGB1 are involved in the induction of autoantibodies elicited in mice infected with mouse hepatitis virus A59. | PubMed |
| Hepatitis B | Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the sleeping beauty transposon system. | PubMed, PubMed |
| Hypotension | Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. | PubMed |
| Hypoxia, Brain | The influence of nimodipine and MK-801 on the brain free arachidonic acid level and the learning ability in hypoxia-exposed rats. | PubMed |
| Infection | Effects of starvation and infection with Schistosoma mansoni on the release rate of free amino acids (FAA) by Biomphalaria glabrata. | PubMed |
| Iron Overload | Deferasirox therapy in children with Fanconi aplastic anemia. | PubMed |
| Kidney Calculi | The amino acid factor in stone formers' and normal urines. | PubMed |
| Kidney Failure, Chronic | Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis. | PubMed |
| Kidney Neoplasms | Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. | PubMed |
| Kidney Neoplasms | Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. | PubMed |
| Kidney Neoplasms | Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. | PubMed |
| Kidney Neoplasms | Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. | PubMed |
| Kidney Neoplasms | Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer. | PubMed |
| Leukemia | Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. | PubMed |
| Leukemia | Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. | PubMed |
| Leukemia | Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo. | PubMed |
| Liver Diseases | Aneuploidy as a mechanism for stress-induced liver adaptation. | PubMed |
| Liver Diseases | Cell fusion is the principal source of bone-marrow-derived hepatocytes. | PubMed |
| Liver Diseases | Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. | PubMed |
| Liver Diseases | Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. | PubMed |
| Liver Failure | Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. | PubMed |
| Liver Failure | Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. | PubMed |
| Liver Neoplasms | Abnormalities in liver iron accumulation during N-2-fluorenylacetamide hepatocarcinogenesis that are dependent or independent of continued carcinogen action. | PubMed |
| Liver Neoplasms | Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide. | PubMed |
| Liver Neoplasms | An enhancing effect of the antihistaminic drug methapyrilene on rat liver carcinogenesis by previously administered N-2-fluorenylacetamide. | PubMed |
| Liver Neoplasms | Dose-dependent reduction of N-2-fluorenylacetamide-induced liver cancer and enhancement of bladder cancer in rats by butylated hydroxytoluene. | PubMed |
| Liver Neoplasms | Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. | PubMed |
| Liver Neoplasms | Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis. | PubMed |
| Lymphoma | Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). | PubMed |
| Lymphoma | Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). | PubMed |
| Lymphoma, Non-Hodgkin | Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. | PubMed |
| Mastocytoma | Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). | PubMed |
| Melanoma | Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. | PubMed |
| Melanoma | Flavone acetic acid induced changes in human endothelial permeability: potentiation by tumour-conditioned medium. | PubMed |
| Melanoma | Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data. | PubMed |
| Melanoma, Experimental | Flavone acetic acid increases the antitumor effect of hyperthermia in mice. | PubMed |
| Melanoma, Experimental | Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia. | PubMed |
| Melanoma, Experimental | In vivo effects of tumor necrosis factor-alpha or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. | PubMed |
| Melanoma, Experimental | Vasoacting agents flavone acetic acid and hydralazine given in combination enhance antitumor effects under condition of hyperthermia. | PubMed |
| Metabolic Diseases | Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase. | PubMed |
| Metabolic Diseases | Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. | PubMed |
| Metabolic Diseases | Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. | PubMed |
| Metabolic Diseases | Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. | PubMed |
| Metabolic Diseases | Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. | PubMed |
| Metabolic Diseases | Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. | PubMed |
| Metabolic Diseases | The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. | PubMed |
| Neoplasm Metastasis | Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. | PubMed |
| Neoplasm Metastasis | Response of primary tumour, spontaneous metastases and recurrence of Lewis lung carcinoma (3LL) to flavone acetic acid (FAA, LM975). | PubMed |
| Neoplasm Metastasis | Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. | PubMed |
| Neoplasm, Residual | Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. | PubMed |
| Neoplasms | 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. | PubMed |
| Neoplasms | Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide. | PubMed |
| Neoplasms | Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. | PubMed |
| Neoplasms | Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy. | PubMed |
| Neoplasms | Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status. | PubMed |
| Neoplasms | Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. | PubMed |
| Neoplasms | Antitumor activity of chemical modified natural compounds. | PubMed |
| Neoplasms | Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. | PubMed |
| Neoplasms | Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. | PubMed |
| Neoplasms | Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. | PubMed |
| Neoplasms | Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. | PubMed |
| Neoplasms | Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA. | PubMed |
| Neoplasms | Combined treatments of heat, radiation, or cytokines with flavone acetic acid on the growth of cultured endothelial cells. | PubMed |
| Neoplasms | Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. | PubMed |
| Neoplasms | Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. | PubMed |
| Neoplasms | Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft. | PubMed |
| Neoplasms | Divergent effects of flavone acetic acid on established versus developing tumour blood flow. | PubMed |
| Neoplasms | Effect of environmental conditions (pH, oxygenation and temperature) on the cytotoxicity of flavone acetic acid and its dimethylaminoethyl ester. | PubMed |
| Neoplasms | Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis. | PubMed |
| Neoplasms | Effect of flavone acetic acid on endothelial cell proliferation: evidence for antiangiogenic properties. | PubMed |
| Neoplasms | Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. | PubMed |
| Neoplasms | Effects of boron neutron capture therapy using borocaptate sodium in combination with a tumor-selective vasoactive agent in mice. | PubMed |
| Neoplasms | Enhancement of hepatocarcinogenesis by sequential administration of chemicals: summation versus promotion effects. | PubMed |
| Neoplasms | Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). | PubMed |
| Neoplasms | Enhancement of mitomycin-C cytotoxicity by combination with flavone acetic acid in a murine tumour. | PubMed |
| Neoplasms | Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. | PubMed |
| Neoplasms | Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. | PubMed |
| Neoplasms | Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. | PubMed |
| Neoplasms | Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. | PubMed |
| Neoplasms | Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites. | PubMed |
| Neoplasms | Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. | PubMed |
| Neoplasms | Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro. | PubMed |
| Neoplasms | Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. | PubMed |
| Neoplasms | Flavone acetic acid and plasma protein binding. | PubMed |
| Neoplasms | Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. | PubMed |
| Neoplasms | Flavone acetic acid as a modifier of endothelial cell function. | PubMed |
| Neoplasms | Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. | PubMed |
| Neoplasms | Flavone acetic acid distribution in human malignant tumors. | PubMed |
| Neoplasms | Flavone acetic acid increases the antitumor effect of hyperthermia in mice. | PubMed |
| Neoplasms | Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia. | PubMed |
| Neoplasms | Flavone acetic acid induced changes in human endothelial permeability: potentiation by tumour-conditioned medium. | PubMed |
| Neoplasms | Flavone acetic acid induces a coagulopathy in mice. | PubMed |
| Neoplasms | Flavone acetic acid pharmacokinetics in nude mice. | PubMed |
| Neoplasms | Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor. | PubMed |
| Neoplasms | Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. | PubMed |
| Neoplasms | Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. | PubMed |
| Neoplasms | Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I. | PubMed |
| Neoplasms | Immunological effects of flavone acetic acid. | PubMed |
| Neoplasms | Inadequate vasculature in solid tumours: consequences for cancer research strategies. | PubMed |
| Neoplasms | Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. | PubMed |
| Neoplasms | Induction of multiple cytokine gene expression and IRF-1 mRNA by flavone acetic acid in a murine macrophage cell line. | PubMed |
| Neoplasms | Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. | PubMed |
| Neoplasms | Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). | PubMed |
| Neoplasms | Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. | PubMed |
| Neoplasms | Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). | PubMed |
| Neoplasms | Inhibition of antitumor effects of flavone acetic acid by cortisone. | PubMed |
| Neoplasms | Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats. | PubMed |
| Neoplasms | Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo. | PubMed |
| Neoplasms | Long-term effects of flavone acetic acid on the growth of a rat tumour. | PubMed |
| Neoplasms | Mechanisms of the inhibitory action of p-hydroxyacetanilide on carcinogenesis by N-2-fluorenylacetamide or N-hydroxy-N-2-fluorenylacetamide. | PubMed |
| Neoplasms | Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. | PubMed |
| Neoplasms | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). | PubMed |
| Neoplasms | Nucleolar organizer regions in hepatocarcinogenesis induced by N-2-fluorenylacetamide in rats: comparison with bromodeoxyuridine immunohistochemistry. | PubMed |
| Neoplasms | Oxidative stress contributes to the anti-proliferative effects of flavone acetic acid on endothelial cells. | PubMed |
| Neoplasms | Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. | PubMed |
| Neoplasms | Potentiation of the cytotoxicity of carboquone by flavone acetic acid combined with hyperthermia. | PubMed |
| Neoplasms | Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. | PubMed |
| Neoplasms | Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). | PubMed |
| Neoplasms | Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. | PubMed |
| Neoplasms | Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid. | PubMed |
| Neoplasms | Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. | PubMed |
| Neoplasms | Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512). | PubMed |
| Neoplasms | Response of primary tumour, spontaneous metastases and recurrence of Lewis lung carcinoma (3LL) to flavone acetic acid (FAA, LM975). | PubMed |
| Neoplasms | Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. | PubMed |
| Neoplasms | Responses of experimental rat tumours and a mouse colon tumour to flavone acetic acid. | PubMed |
| Neoplasms | Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. | PubMed |
| Neoplasms | Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. | PubMed |
| Neoplasms | Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. | PubMed |
| Neoplasms | Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature. | PubMed |
| Neoplasms | Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. | PubMed |
| Neoplasms | Small-molecule cytokine inducers causing tumor necrosis. | PubMed |
| Neoplasms | Studies with a panel of tumours having a variable sensitivity to FAA, to investigate its mechanism of action. | PubMed |
| Neoplasms | Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 1: 6-Methyl derivatives. | PubMed |
| Neoplasms | Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer. | PubMed |
| Neoplasms | Systemic effects of FAA are enhanced by implanted tumours. | PubMed |
| Neoplasms | Testicular mesotheliomas in rats exposed to N-2-fluorenylacetamide (FAA). | PubMed |
| Neoplasms | The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells. | PubMed |
| Neoplasms | The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. | PubMed |
| Neoplasms | The in vivo interaction between flavone acetic acid and hyperthermia. | PubMed |
| Neoplasms | The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours. | PubMed |
| Neoplasms | The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids. | PubMed |
| Neoplasms | The Sir Mark Oliphant Conferences: international frontiers of science and technology. | PubMed |
| Neoplasms | The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. | PubMed |
| Neoplasms | Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. | PubMed |
| Neoplasms | Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data. | PubMed |
| Neoplasms | Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512). | PubMed |
| Neoplasms | Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. | PubMed |
| Neoplasms | Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. | PubMed |
| Neoplasms | Vasoacting agents flavone acetic acid and hydralazine given in combination enhance antitumor effects under condition of hyperthermia. | PubMed |
| Obesity | Co-morbid conditions in overweight and obese airmen: trends and aeromedical implications. | PubMed |
| Osteoporosis | Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. | PubMed |
| Osteosarcoma | Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. | PubMed |
| Osteosarcoma | Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. | PubMed |
| Osteosarcoma | Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo. | PubMed |
| Pain | Functional disassociation of the central and peripheral fatty acid amide signaling systems. | PubMed |
| Pain | The enzymatic inactivation of the fatty acid amide class of signaling lipids. | PubMed |
| Porphyria, Acute Intermittent | Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. | PubMed |
| Porphyrias | Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. | PubMed |
| Porphyrias | [delta-Aminolevulinate dehydratase deficiency] | PubMed |
| Porphyrias, Hepatic | [delta-Aminolevulinate dehydratase deficiency] | PubMed |
| Pregnancy, High-Risk | Fumarylacetoacetase activity in cultured and non-cultured chorionic villus cells, and assay in two high-risk pregnancies. | PubMed |
| Pulmonary Heart Disease | Electrophysiological study of infant and adult rats under acute intoxication with fluoroacetamide. | PubMed |
| Renal Insufficiency | [False anastomotic aneurysms after aorto-femoral prosthesis. Detection, prevention and treatment] | PubMed |
| Rhabdomyosarcoma | Responses of experimental rat tumours and a mouse colon tumour to flavone acetic acid. | PubMed |
| Sarcoma | Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. | PubMed |
| Sarcoma | Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. | PubMed |
| Sarcoma | Long-term effects of flavone acetic acid on the growth of a rat tumour. | PubMed |
| Seizures | Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities. | PubMed |
| Sepsis | [False anastomotic aneurysms after aorto-femoral prosthesis. Detection, prevention and treatment] | PubMed |
| Starvation | Effect of starvation on free histidine and amino acids in white muscle of milkfish Chanos chanos. | PubMed |
| Starvation | [A study on the constitutional change of taurine and other free amino acids during the fetal development (author's transl)] | PubMed |
| Stroke | Clinical evaluation of a fully automated model-based algorithm to calculate left ventricular volumes and ejection fraction using multidetector computed tomography. | PubMed |
| Testicular Neoplasms | Testicular tumor in an aviator. | PubMed |
| Thrombosis | Flavone-8-acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo. | PubMed |
| Tyrosinemias | A GC/MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: An analytical tool for tyrosinemia type I. | PubMed |
| Tyrosinemias | A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation. | PubMed |
| Tyrosinemias | A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. | PubMed |
| Tyrosinemias | A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report. | PubMed |
| Tyrosinemias | A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | AAV Vectors Containing rDNA Homology Display Increased Chromosomal Integration and Transgene Persistence. | PubMed |
| Tyrosinemias | Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Animal models reveal pathophysiologies of tyrosinemias. | PubMed |
| Tyrosinemias | Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue. | PubMed |
| Tyrosinemias | Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. | PubMed |
| Tyrosinemias | Cloning and expression analysis of a cDNA encoding fumarylacetoacetate hydrolase: post-transcriptional modulation in rat liver and kidney. | PubMed |
| Tyrosinemias | Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. | PubMed |
| Tyrosinemias | Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient. | PubMed |
| Tyrosinemias | Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer. | PubMed |
| Tyrosinemias | Current strategies for the treatment of hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase. | PubMed |
| Tyrosinemias | Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Deficiency of fumarylacetoacetase without hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I. | PubMed |
| Tyrosinemias | Diagnosis and management of tyrosinemia type I. | PubMed |
| Tyrosinemias | Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. | PubMed |
| Tyrosinemias | Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). | PubMed |
| Tyrosinemias | DNA damage and repair in mammalian cells exposed to p-hydroxyphenylpyruvic acid. | PubMed |
| Tyrosinemias | Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. | PubMed |
| Tyrosinemias | Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. | PubMed |
| Tyrosinemias | Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | Expression and post-translational modification of human 4-hydroxy-phenylpyruvate dioxygenase. | PubMed |
| Tyrosinemias | Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). | PubMed |
| Tyrosinemias | Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. | PubMed |
| Tyrosinemias | Gene expression profiles of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays. | PubMed |
| Tyrosinemias | Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. | PubMed |
| Tyrosinemias | Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. | PubMed |
| Tyrosinemias | Hereditary tyrosinemia type 1 metabolites impair DNA excision repair pathways. | PubMed |
| Tyrosinemias | Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship. | PubMed |
| Tyrosinemias | Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. | PubMed |
| Tyrosinemias | Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein. | PubMed |
| Tyrosinemias | Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis. | PubMed |
| Tyrosinemias | Hereditary tyrosinemias (type I): a new vista on tyrosine toxicity and cancer. | PubMed |
| Tyrosinemias | High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. | PubMed |
| Tyrosinemias | Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I. | PubMed |
| Tyrosinemias | Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin. | PubMed |
| Tyrosinemias | Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients. | PubMed |
| Tyrosinemias | Impaired DNA repair and genomic stability in hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. | PubMed |
| Tyrosinemias | In vivo selection of hepatocytes transduced with adeno-associated viral vectors. | PubMed |
| Tyrosinemias | In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I. | PubMed |
| Tyrosinemias | Liver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cells. | PubMed |
| Tyrosinemias | Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | Long-term outcome of living donor liver transplantation in a Thai boy with hereditary tyrosinemia type I: a case report. | PubMed |
| Tyrosinemias | Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. | PubMed |
| Tyrosinemias | Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. | PubMed |
| Tyrosinemias | Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. | PubMed |
| Tyrosinemias | No evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients. | PubMed |
| Tyrosinemias | Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1. | PubMed |
| Tyrosinemias | Nucleotide sequence of a cDNA encoding murine fumarylacetoacetate hydrolase. | PubMed |
| Tyrosinemias | On the enzymic defects in hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis. | PubMed |
| Tyrosinemias | Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells. | PubMed |
| Tyrosinemias | Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase. | PubMed |
| Tyrosinemias | Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment. | PubMed |
| Tyrosinemias | Self-induced correction of the genetic defect in tyrosinemia type I. | PubMed |
| Tyrosinemias | Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients. | PubMed |
| Tyrosinemias | Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. | PubMed |
| Tyrosinemias | Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. | PubMed |
| Tyrosinemias | Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. | PubMed |
| Tyrosinemias | Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I. | PubMed |
| Tyrosinemias | Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver. | PubMed |
| Tyrosinemias | Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia. | PubMed |
| Tyrosinemias | The Caenorhabditis elegans K10C2.4 Gene Encodes a Member of the Fumarylacetoacetate Hydrolase Family: A CAENORHABDITIS ELEGANS MODEL OF TYPE I TYROSINEMIA. | PubMed |
| Tyrosinemias | The effects of early treatment of hereditary tyrosinemia type I in infancy by orthotopic liver transplantation. | PubMed |
| Tyrosinemias | The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency. | PubMed |
| Tyrosinemias | The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. | PubMed |
| Tyrosinemias | The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. | PubMed |
| Tyrosinemias | The nephropathy of type I tyrosinemia after liver transplantation. | PubMed |
| Tyrosinemias | The pathophysiology and treatment of hereditary tyrosinemia type 1. | PubMed |
| Tyrosinemias | The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase. | PubMed |
| Tyrosinemias | Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase. | PubMed |
| Tyrosinemias | Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. | PubMed |
| Tyrosinemias | Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. | PubMed |
| Tyrosinemias | Tyrosinaemia--treatment and outcome. | PubMed |
| Tyrosinemias | Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. | PubMed |
| Tyrosinemias | Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene. | PubMed |
| Tyrosinemias | Tyrosinemia type I: a clinico-laboratory case report. | PubMed |
| Tyrosinemias | Tyrosinemia: the Quebec experience. | PubMed |
| Tyrosinemias | Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine. | PubMed |
| Tyrosinemias | Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia. | PubMed |
| Tyrosinemias | Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia. | PubMed |
| Tyrosinemias | [Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I]. | PubMed |
| Tyrosinemias | [delta-Aminolevulinate dehydratase deficiency] | PubMed |
| Tyrosinemias | [Evolution of a case of tyrosinemia type I treated with NTBC] | PubMed |
| Tyrosinemias | [Juvenile form of tyrosinemia type I] | PubMed |
| Urinary Bladder Neoplasms | Dose-dependent reduction of N-2-fluorenylacetamide-induced liver cancer and enhancement of bladder cancer in rats by butylated hydroxytoluene. | PubMed |
| Vertigo | Benign paroxysmal positional vertigo in an airline pilot. | PubMed |
PRINT
